TrialDiabetes, obesity & metabolism2026

Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease.

Jelle M Beernink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.